Co-biomodulation with arsenic trioxide in multiple myeloma
- 20 February 2001
- journal article
- editorial
- Published by Elsevier in Leukemia Research
- Vol. 25 (3), 237-239
- https://doi.org/10.1016/s0145-2126(00)00144-2
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cellsLeukemia Research, 2001
- Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic TrioxideJournal of Clinical Oncology, 2000
- Immunomodulation of cancer: potential use of selectively replicating agentsJournal of Clinical Investigation, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acidBritish Journal of Cancer, 1999
- Arsenic Trioxide, a Novel Mitochondriotoxic Anticancer Agent?JNCI Journal of the National Cancer Institute, 1999
- Arsenic — New Life for an Old PotionNew England Journal of Medicine, 1998
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Influence of Malignant Cell Clonogenic Capacities and Position Along the Maturation Pathway on Their Susceptibility to Lymphokine-Activated Killer Cell CytotoxicityLeukemia & Lymphoma, 1998
- Differentiation‐related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variantsInternational Journal of Cancer, 1992